Generic Name and Formulations:
Butalbital 50mg, acetaminophen 325mg, caffeine 40mg; tabs; caps.
Various generic manufacturers
- Effect of Maternal Caffeine Intake on Childhood Growth
- Dexcom G6 Integrated Continuous Glucose Monitoring System Gets FDA Approval
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
Indications for Butalbital/Acetaminophen/Caffeine:
Tension (or muscle contraction) headache.
1–2 tabs or caps every 4hrs as needed; max 6 daily.
Drug abusers. Severe hepatic or renal impairment (monitor). Acute abdominal conditions. Discontinue if serious skin rash or hypersensitivity reactions occur. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Barbiturate + analgesic.
May potentiate effects of alcohol, general anesthetics, tranquilizers, sedative-hypnotics, or other CNS depressants or narcotic analgesics; avoid. MAOIs may enhance CNS effects of butalbital. May cause false (+) urine test for 5-hydroxyindoleacetic acid.
Drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, intoxicated feeling; hepatotoxicity (APAP doses >4g/day); rare: serious skin reactions, hypersensitivity.
Formerly known under the brand name Esgic.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
- New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D
- Peer-Led Education Helps Physicians Save Time With EHRs
- As Immigration Policies Tighten, Physician Shortage Concerns Grow